# GSK Plc’s Nucala approved in China as a treatment for CRSwNP

- Link: https://www.directorstalkinterviews.com/gsk-plcs-nucala-approved-in-china-as-a-treatment-for-crswnp/4121182331
- Published: 2025-01-03T07:20:25+00:00
- Author: Amilia Stone

[GSK plc](https://www.directorstalkinterviews.com/ftse-company/glaxosmithkline-plc/gsk.l)(
LSE/NYSE: GSK) today announced that the China National Medical Products Administration
has approved _Nucala_ (mepolizumab), a monoclonal antibody that targets interleukin-
5 (IL-5), as an add-on therapy with intranasal corticosteroids for the treatment
of adult patients with CRSwNP for whom therapy with systemic corticosteroids and/
or surgery do not provide adequate disease control.

·  Mepolizumab is the only anti-interleukin-5 approved in China for the treatment
of adults with inadequately controlled chronic rhinosinusitis with nasal polyps (
CRSwNP)

·  Around 30 million people in China live with CRSwNP and experience symptoms such
as sleep disturbance, breathing problems and loss of smell

·  This is the third indication for mepolizumab in China for an IL-5 mediated condition

> **Kaivan Khavandi, SVP, Global Head of Respiratory/Immunology R&D at GSK**** said:**“
> We are delighted that _Nucala_ has been approved in China as a treatment for CRSwNP,
> a chronic condition for which new and effective treatments are needed. Patients
> now have a non-surgical option available to them and an alternative to repeated
> exposure to oral corticosteroids.”

It is estimated that about 107 million people in China suffer from chronic sinusitis,
about 1/3 of whom have chronic sinusitis with nasal polyps.^(1-4) People with CRSwNP
experience symptoms such as nasal obstruction, loss of smell, facial pressure, sleep
disturbance and nasal discharge, which can significantly affect their emotional 
and physical well-being.^(4-6)

CRSwNP is caused by chronic inflammation of the nasal lining that can cause soft
tissue growth, known as nasal polyps, that develop in the sinuses and nasal cavity.
^(5,6) Up to 80% of patients with CRSwNP have type 2  inflammation, which is associated
with more severe disease and nasal polyp recurrence and can be detected by blood
eosinophil count, a biomarker measured by a simple blood test.^(6-9) IL-5 is a key
cytokine driving this type 2 inflammation and is present at high levels in nasal
polyp tissue.^(4-8) Although surgery can be effective at removing polyps, the underlying
type 2 inflammation means they have a tendency to regrow.^(9,10)

The approval is based on results of the phase III MERIT trial, which studied the
efficacy and safety of mepolizumab over a 52-week period versus placebo in a population
of Japanese, Chinese and Russian patients with inadequately controlled CRSwNP, and
is supported by data from the global phase III SYNAPSE study, which explored the
effect of mepolizumab versus placebo in more than 400 patients with CRSwNP.^(5,10)

Mepolizumab is already approved in China as an add-on maintenance treatment for 
adults and adolescents aged 12 years and older with severe eosinophilic asthma as
well as for adults with eosinophilic granulomatosis with polyangiitis.  

**References**

**1.   ** Liu Z, et al. Chinese Society of Allergy and Chinese Society of Otorhinolaryngology-
Head and Neck Surgery Guideline for Chronic Rhinosinusitis. _Allergy_ _Asthma Immunol
Res_. 2020;12(2):176-237.

**2.   ** Wu Q, et al. Efficacy and safety of omalizumab in chronic rhinosinusitis
with nasal polyps: a systematic review and meta-analysis of randomised controlled
trials. BMJ Open. 2021 Sep;11(9):e047344.

**3.   ** Bachert C, et al. Burden of Disease in Chronic Rhinosinusitis with Nasal
Polyps. _J Asthma Allergy_. 2021;14:127-134.

**4.   ** Wang Chengshuo, Zhang Luo. Biologics for the treatment of chronic rhinosinusitis
with nasal polyps [J] . Chinese Journal of Otolaryngology-Head and Neck Surgery,
2023, 58(3) : 193-199.

**5.   ** Han JK, et al. Mepolizumab for chronic rhinosinusitis with nasal polyps(
SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial. _Lancet
Respir Med._ 2021;9(10):1141-1153.

**6.   ** Bachert C, et al. EUFOREA expert board meeting on uncontrolled severe 
chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: Definitions and
management. _J Allergy Clin Immunol_. 2021;147(1):29-36.

**7.   ** Kato A, et al. Endotypes of chronic rhinosinusitis: Relationships to disease
phenotypes, pathogenesis, clinical findings, and treatment approaches. _Allergy_.
2022;77(3):812-826.

**8.   ** De Corso E, et al. How to manage recurrences after surgery in CRSwNP patients
in the biologic era: a narrative review. _Acta Otorhinolaryngol Ital_. 2023;43(2
Suppl. 1):S3-S13.

**9.   ** Chen S, et al. Systematic literature review of the epidemiology and clinical
burden of chronic rhinosinusitis with nasal polyposis. _Curr Med Res Opin._ 2020;36(
11):1897-1911.

**10. ** Fujieda S, et al. Mepolizumab in CRSwNP/ECRS and NP: The Phase III randomised
MERIT trial in Japan, China and Russia. _Rhinology._  26 July 2024.   doi: 10.4193/
Rhin24.156. Online ahead of print.

_GSK continues to build on decades of pioneering work to deliver more ambitious 
treatment goals, develop the next generation standard of care, and redefine the 
future of respiratory medicine for hundreds of millions of people with respiratory
diseases._

Share on:
